Filtered By:
Specialty: Drugs & Pharmacology
Infectious Disease: Outbreaks

This page shows you your search results in order of date.

Order by Relevance | Date

Total 15 results found since Jan 2013.

Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs
Drug Metab Pharmacokinet. 2021 Oct 10;41:100424. doi: 10.1016/j.dmpk.2021.100424. Online ahead of print.ABSTRACTNucleic acid therapeutics are developing into precise medicines that can manipulate specific genes. However, the development of safe and effective delivery system for the target cells has remained a challenge. Lipid nanoparticles (LNPs) have provided a revolutionary delivery system that can ensure multiple clinical translation of RNA-based candidates. In 2018, Patisiran (Onpattro) was first approved as an LNP-based siRNA drug. In 2020, during the coronavirus disease 2019 (COVID-19) outbreak, LNPs have enabled the...
Source: Drug Metabolism and Pharmacokinetics - November 10, 2021 Category: Drugs & Pharmacology Authors: Yuta Suzuki Hiroshi Ishihara Source Type: research

Viral infection: New tricks to treat Ebola
Nature Reviews Drug Discovery 15, 675 (2016). doi:10.1038/nrd.2016.191 Author: Megan Cully Although there are currently no major outbreaks of Ebola, new ones are likely to emerge in the coming years. Ideally, treatments will be strain-adaptable. A new paper in Nature Microbiology demonstrates that a Sudan ebolavirus (SUDV)-targeting small interfering RNA (siRNA) can prevent death
Source: Nature Reviews Drug Discovery - September 28, 2016 Category: Drugs & Pharmacology Authors: Megan Cully Tags: Research Highlight Source Type: research

Subretinal transfection of chitosan-loaded TLR3-siRNA for the treatment of experimental autoimmune uveitis.
Abstract The local interaction between retinal pigment epithelium (RPE) and immigrated effector T cells is crucial for the pathogenesis of autoimmune uveitis. After being activated by the pattern recognition receptors (PRRs) signaling pathway, RPE can present the antigen reactivated invading autoreactive T cells, resulting in uveitis. In the present study, we showed that the transfection of chitosan-loaded TLR3-siRNA toward RPE could effectively remit experimental autoimmune uveitis (EAU) in B10RIII mice. Initially, we verified the constitutive expression of Tlr3 in RPE at high levels, which was not altered in the...
Source: European Journal of Pharmaceutics and Biopharmaceutics - September 17, 2013 Category: Drugs & Pharmacology Authors: Chen S, Yan H, Sun B, Zuo A, Liang D Tags: Eur J Pharm Biopharm Source Type: research